Monograph
A10BJ05 - Dulaglutide |
Propably not porphyrinogenic |
PNP |
Important Information
Nausea and vomiting are reported are very common side effects of dulaglutide that may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Side effects
Nausea and vomiting is reported as very common adverse reactions of dulaglutid especially when used in doses of 1,5 mg weekly (Thompson 2015). These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Dulaglutide is not metabolized by CYP, and is not an inducer or inhibitor of CYP.
Chemical description
Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Therapeutic characteristics
Dulaglutide is indicated in adults with type 2 diabetes mellitus to improve glycaemic control
It is administered once weekly as a subcutaneous injection.
Metabolism and pharmacokinetics
Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways (SPC).
Dulaglutide is not expected to affect the cytochrome P450 system, and no CYP related interactions are listed in drug-drug interaction databases.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions.
Nucleic Acids Res. 2010 Jan;38(Database issue). |
19934256 |
| 2. | Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Thompson AM, Trujillo JM. Ann Pharmacother. 2015 Mar;49(3):351-9. |
25565404 |
| * | Drug interaction databases | |
| 3. | Lexi-Interact, via UpToDate.
|
|
| 4. | Micromedex® 2.0 (online). Drug Interactions). (08.12.2016).
|
|
| 5. | The Danish Health and Medicines Authority. The drug interaction database.
|
|
| * | Summary of Product Characteristics | |
| 6. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Trulicity.
|
|
| * | Other sources | |
| 7. | Interaction databases:
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024